AstraZeneca's Type-2 Diabetes Drug Qtrilmet Approved in the EU

Date : 11/15/2019 @ 7:41AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 47.62  -0.58 (-1.20%) @ 12:59AM
After Hours
Last Trade
Last $ 47.62 ◊ 0.00 (0.00%)

AstraZeneca's Type-2 Diabetes Drug Qtrilmet Approved in the EU

Astrazeneca (LSE:AZN)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

By Adriano Marchese

 

AstraZeneca PLC (AZN.LN) said Friday that its Qtrilmet drug has been approved in the European Union to treat type-2 diabetes.

The drug maker said that Qtrilmet, a modified-release tablet to improve glycaemic control in adults with type-2 diabetes, was approved by the European Commission, based on data from five Phase 3 trials.

The drug was approved in the U.S. in May under the name Qternmet XR.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

November 15, 2019 02:26 ET (07:26 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.